7.20
7.20 (0%)
As of Feb 14, 2025
Tenax Therapeutics, Inc. [TENX]
Source:
Company Overview
Tenax Therapeutics is a clinical-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. We employ a clinician-focused drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology.
| Country | United States |
| Headquarters | chapel hill, north carolina |
| Phone Number | (919) 855-2100 |
| Industry | manufacturing |
| CEO | Christopher T. Giordano |
| Website | www.tenaxthera.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $19.5 |
| Net Income | $17.6 |
| Net Cash | $85.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | 32.5% |
| Profit as % of Stockholder Equity | 19.1% |
Management Effectiveness
| Return on Equity | 19.1% |
| Return on Assets | 18.2% |
| Turnover Ratio | |
| EBITA | $19.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $96.7 |
| Total Liabilities | $4.7 |
| Operating Cash Flow | $-14.8 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $99.9 |
